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Abstract
Single and multiple resistance to antibacterial drugs currently in use is spreading,
since they act against only a very small number of molecular targets; ﬁnding novel
targets for anti-infectives is therefore of great importance. All protein sequences from
three pathogens (Staphylococcus aureus, Mycobacterium tuberculosis and Escherichia
coli O157:H7 EDL993) were assessed via comparative genomics methods for their
suitability as antibacterial targets according to a number of criteria, including the
essentiality of the protein, its level of sequence conservation, and its distribution in
pathogens, bacteria and eukaryotes (especially humans). Each protein was scored and
ranked based on weighted variants of these criteria in order to prioritize proteins as
potential novel broad-spectrum targets for antibacterial drugs. A number of proteins
proved to score highly in all three species and were robust to variations in the scoring
system used. Sensitivity analysis indicated the quantitative contribution of each metric
to the overall score. After further analysis of these targets, tRNA methyltransferase
(trmD) and translation initiation factor IF-1 (infA) emerged as potential and novel
antimicrobial targets very worthy of further investigation. The scoring strategy used
might be of value in other areas of post-genomic drug discovery. Copyright  2004
John Wiley & Sons, Ltd.
Keywords: genomics; antibacterial; antimicrobial; pathogen; virulence; compara-
tive genomics; antibiotics; bioinformatics
Introduction
Within two decades of the introduction of peni-
cillin, the majority of the existing classes of
antibacterial drugs had been discovered by system-
atic screening of natural product libraries. Remark-
ably, no new chemical classes of active antibacte-
rial drugs were successfully introduced for a further
30 years (Hancock and Knowles, 1998). Table 1
shows the very restricted set of modes of action of
the major antibacterial drugs currently in use.
Microorganisms have also shown themselves to
be extremely versatile in overcoming the effects
of antibacterial drugs. Bacteria have developed
a variety of resistance mechanisms and lateral
gene transfer mechanisms allow this resistance
to be passed between different bacterial strains
and species (Davies, 1994; Heinemann, 1999).
Antibacterial resistance has developed steadily as
new agents have been introduced, and the past
10–15 years have shown a dramatic increase in the
occurrence of resistant populations of microbes in
both community and hospital environments (Stru-
elens, 1998).
Measures such as chemical modiﬁcation of exist-
ing antibacterial drugs and the development of
inhibitors of resistance genes will have a signif-
icant impact on antibacterial therapy in the short
term. However, it is obvious that new drug tar-
gets need to be found if the use of antibacterial
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Table 1. Mode of action of the principal established antibacterial drugs
Drug/class Function inhibited Molecular target
β-Lactams Peptidoglycan synthesis Transpeptidases and carboxpeptidases
Bacitracin Peptidoglycan synthesis Undecaprenyl pyrophosphate
D-Cycloserine Peptidoglycan synthesis D-alanine racemase and D-alanyl-D-alanine synthetase
Fosfomycin Peptidoglycan synthesis UDP-N-acetylglucosamine enolpyruvyl transferase
Glycopeptides Peptidoglycan synthesis Cell wall peptidoglycan
Quinolones DNA replication/transcription Gyrase and topoisomerase IV
Rifamycins Transcription RNA polymerase
Aminoglycosides Protein synthesis 30S ribosomal subunit
Chloramphenicol Protein synthesis 50S ribosomal subunit
Fusidic adid Protein synthesis Elongation factor G
Macrolides Protein synthesis 50S ribosomal subunit
Oxazolidinones Protein synthesis 50S ribosomal subunit
Streptogramins Protein synthesis 50S ribosomal subunit
Tetracyclines Protein synthesis 30S ribosomal subunit
Mupirocin Charging of isoleucyl tRNA Isoleucyl tRNA synthetase
Sulphonamides Folate synthesis Dihydropteroate synthetase
Trimethoprim Folate synthesis Dihydrofolate reductase
After Chopra et al. (2002).
drugs is to continue successfully (Schmid, 1998).
To this end, genomic approaches are providing a
new strategy by revealing new molecular targets
that are giving rise to novel antibacterial agents
(Allsop and Illingworth, 2002; Dougherty et al.,
2002; Haney et al., 2002; Isaacson, 2002; Ji, 2002;
McDevitt and Rosenberg, 2001), as these new
agents are unlikely to face the current problems
of established mechanisms of resistance (McDevitt
and Rosenberg, 2001). In anti-infective research,
the inevitable selection for resistant strains means
that drugs with multiple targets may be preferred
(e.g. multiple penicillin-binding proteins or multi-
ple forms of two-component systems; Stephenson
and Hoch, 2002; Stephenson and Hoch, 2004). In
other pharmaceutical areas it is encouraging that
the rational utility of traditional targets is being
conﬁrmed by systematic knock-out studies (Zam-
browicz and Sands, 2003).
With the release of data from numerous sequenc-
ing projects, the number of potential drug targets
has increased massively. However, not all of these
molecules will become drug targets (Hopkins and
Groom, 2002), and the big challenge is to select
the targets most relevant for a given situation (Ter-
stappen and Reggiani, 2001).
Machine learning methods seek to devise new
ideas and hypotheses from more or less unstruc-
tured data (Gillies, 1996; Kell and Oliver, 2004;
Mitchell, 1997; Mjolsness and DeCoste, 2001).
It has been shown that such data-driven strate-
gies can be used to identify novel drug targets
(Spaltmann et al., 1999). A number of metrics are
chosen which should be properties of a potential
drug target, such as essentiality and speciﬁcity.
Each potential target in a genome of interest is
scored for these properties. These scores can be
weighted differently to add more or less emphasis
to any particular property. This scoring system can
be tuned so that targets which have already been
identiﬁed score highly, showing that the scoring
system is capable of identifying useful targets. Pre-
viously unidentiﬁed genes may also score highly,
and these can be prioritized as potential drug targets
for further study. The top-scoring gene in the study
carried out by Spaltmann et al. (1999) on antifun-
gal targets was α,α-trehalose-phosphate synthase,
a gene which had never before been suggested
as a potential drug target. This shows that post-
genomic research has much to offer in terms of
novel target identiﬁcation (Allsop and Illingworth,
2002; Buysse, 2001; Dougherty et al., 2002; Glass
et al., 2002; Haney et al., 2002; Isaacson, 2002;
Ji, 2002; Knowles and King, 1998; McDevitt and
Rosenberg, 2001; Payne et al., 2001a, 2001b; Will-
ins et al., 2002).
In the present study a number of criteria were
chosen on which to characterize proteins as targets.
These were suggested by the extensive literature
on the subject (see e.g. Alksne, 2002; Allsop and
Illingworth, 2002; McDevitt and Rosenberg, 2001;
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Projan, 2002; Spaltmann et al., 1999; Terstappen
and Reggiani, 2001). A full list of the criteria used
is given in the Methods section.
Methods
Data collection and motives
Data were collected from three pathogenic bacterial
species, Staphylococcus aureus, Escherichia coli
O157:H7 EDL993 and Mycobacterium tuberculo-
sis. These species were chosen as they represent
a broad cross-section of bacterial types. Targets
which prove to score well in these three species
will probably be good targets across a broad spec-
trum of pathogens.
The entire set of sequences of proteins encoded
by S. aureus, E. coli O157:H7 EDL993 and M.
tuberculosis were downloaded from the NCBI
website (http://www.ncbi.nlm.nih.gov/PMGifs/
Genomes/micr.html). Each protein was then char-
acterized by a number of criteria which could then
be used to prioritize the most suitable proteins as
potential antibacterial targets.
A Perl program carried out most of the char-
acterization automatically (see Figure 1 for an
overview). Each protein was parsed to ﬁnd the gene
index (gi) number and name of the protein. If the
function of the protein was known, or if a function
had been assigned to the protein on the basis of
sequence homology, then this was noted.
Each protein was then submitted to a BLAST
(Altschul et al., 1990, 1997) search (BLASTp,
using default parameters except for an ‘expectation
value’ of 0.01) against a local copy of the SwissProt
database (ftp://ftp.ebi.ac.uk/pub/). The SwissProt
database was used because it is well curated,
well annotated, non-redundant, and since entries
are easily parseable due to its consistent format.
There also exist a large number of associated ﬁles
and websites which use SwissProt-style codes (for
species and gene/protein names). Using SwissProt
therefore allows these resources to be integrated
easily into the program, thus making efﬁcient
automation possible.
The results of each BLAST search were parsed
to ﬁnd how many homologues of this protein
existed in bacteria, pathogenic bacteria, eukary-
otes, mice and Lactobacillus. This was done by
comparing the SwissProt species ID code of each
hit against a look-up table that listed the classiﬁ-
cation of the organism (http://ca.expasy.org/cgi-
bin/speclist). A list of bacteria treated as pathoge-
nic in this study is given in Table 2. Bacteria may
or may not act as pathogens, depending on the cir-
cumstances and the host, and so the list given here
covers a broad range of pathogens but is perhaps
not completely comprehensive.
The presence of homologues in mice was con-
sidered important not only as this will allow targets
which are present in higher organisms to be further
down-weighted, but also because further down the
line the target’s absence in mice will make animal
trials more effective. Lactobacillus spp. are con-
sidered to beneﬁcial or probiotic bacteria, so using
this metric might be able to prioritize targets which
diminish any unwanted side-effects of a new drug.
The scores of BLAST hits against pathogens
were also parsed to ﬁnd how well conserved
a particular gene is amongst pathogens. Obvi-
ously a protein that is well-conserved across many
pathogens will make a better target for broad-
spectrum antibacterial drugs. A high degree of
conservation may also mean that mutations in the
protein are not tolerated, such that resistance is
less likely to emerge. The numbers of identical
residues in each pathogenic hit compared to the
query sequence were summed and then divided by
the number of hits against pathogens. This number
was normalized by dividing by the length of the
query sequence, to give a ratio of conservation for
this protein across pathogens.
The query protein was submitted to BLAST
separately against the human genome (protein
sequences) (ftp://ftp.ncbi.nih.gov/genomes/H
sapiens/protein/) and the number of hits was
recorded. The closest hit against a human protein
was also recorded, with a ratio of similarity given
by the number of positive residue matches (matches
where amino acids are identical or have similar
biochemical properties) divided by the length of
the query sequence. The number of positives was
chosen so as to err on the side of caution. Any
drug designed against a particular bacterial protein
may act just as well against a human protein, even
if certain key residues are not identical. Similar-
ity of residues may be enough for activity. This
metric was included so that potential targets which
were not so similar to human proteins would not
be so heavily penalized. Even if a human homo-
logue does exist, it may still be possible (e.g. using
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Read in genome from
file and split into
individual protein
sequences (FASTA
format)
For each query protein
carry out a restricted
BLAST search against
essential genes in Bacilus
subtilis, Escherichia coli K12,
Mycobacterium tuberculosis
and Staphylococcus aureus
(expectation value 0.01)
For each query protein
carry out a restricted
BLAST search against
virulence genes in
Bacillus anthracis,
Escherichia coli O157:H7
EDL993, Mycobacterium
tuberculosis, Neisseria
Meningitidis and
Staphylococcus aureus
(expectation value 0.01)
For each query protein
carry out another BLAST
search of SwissProt (with
higher expectation value
1×10-10) and parse output
to find any hits which are
known antibacterial targets
or which have a structure
in the Protein Data Bank
Output the information for
each protein to file. This
can then be used to score
and rank proteins
according to potential as
novel broad-spectrum
drug targets
Take each protein
sequence in turn and
parse to find the gene
name, gi number and
whether a function has
been assigned to the
protein
BLAST each protein
against the SwissProt
database (expectation
value 0.01)
Parse the BLAST
output from each
protein to find
taxonomic distribution
of protein and its
conservation in
pathogens
BLAST each protein
against all protein
sequences from
human (expectation
value 0.01). Find
number of human
homologues and
similarity of closest
human hit.
Figure 1. Flow chart illustrating the process of data collection
structure–activity relationship studies) to design a
drug which targets only the bacterial version of the
protein.
The query gene was then again submitted to
the BLAST program to ﬁnd homologues which
are known antibacterial targets or whose structures
have been deciphered. This time an ‘expectation
value’ of 1 × 10−10 was used, as to infer suitability
as a target or structural similarity it was thought
safer to report only very close homologues.
After running the BLAST algorithm, the output
was parsed to ﬁnd whether the query gene was
homologous to a known antibacterial target. This
was done by comparing the SwissProt gene ID
against a list of SwissProt IDs (from the ExPASy
website: http://ca.expasy.org/enzyme/) of proteins
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Table 2. List of bacteria treated as pathogenic in this study
Acinetobacter calcoaceticus Klebsiella pneumoniae Shigella dysenteriae
Bacillus anthracis Legionella pneumophila Shigella ﬂexneri
Bacillus cereus Leptospira interrogans Staphylococcus aureus
Bordetella pertussis Listeria monocytogenes Staphylococcus aureus strain Mu50/ATCC 700699
Borrelia burgdorferi Moraxella catarrhalis Staphylococcus aureus strain MW2
Brucella abortus Moraxella lacunata Staphylococcus aureus strain N315
Brucella melitensis Mycobacterium leprae Staphylococcus capitis
Brucella suis Mycobacterium tuberculosis Staphylococcus epidermidis
Campylobacter jejuni Mycoplasma fermentans Staphylococcus saprophyticus
Chlamydia muridarum Mycoplasma genitalium Streptococcus agalactiae
Chlamydia pneumoniae Mycoplasma hominis Streptococcus agalactiae serotype III
Chlamydia trachomatis Mycoplasma penetrans Streptococcus agalactiae serotype V
Clostridium botulinum Mycoplasma pneumoniae Streptococcus mutans
Clostridium perfringens Neisseria gonorrhoeae Streptococcus pneumoniae
Clostridium tetani Neisseria meningitidis Streptococcus pyogenes
Corynebacterium diphtheriae Neisseria meningitidis serogroup A Streptococcus pyogenes serotype M18
Enterococcus faecalis Neisseria meningitidis serogroup B Streptococcus pyogenes serotype M3
Enterococcus faecium Neisseria meningitidis serogroup C Streptococcus pyogenes serotype M5
Escherichia coli O111:H− Pasteurella multocida Treponema pallidum
Escherichia coli O127:H6 Propionibacterium acnes Tropheryma whipplei
Escherichia coli O157:H7 Proteus mirabilis Ureaplasma urealyticum
Escherichia coli O6 Providencia rettgeri Vibrio cholerae
Flavobacterium meningosepticum Providencia stuartii Vibrio parahaemolyticus
Francisella tularensis Pseudomonas aeruginosa Vibrio vulniﬁcus
Fusobacterium nucleatum Rickettsia conorii Wolinella recta
Haemophilus ducreyi Rickettsia prowazekii Wolinella succinogenes
Haemophilus inﬂuenzae Salmonella cholerae-suis Xanthomonas maltophilia
Haemophilus parainﬂuenzae Salmonella enteritidis Yersinia pestis
Helicobacter pylori Salmonella typhi
Helicobacter pylori J99 Salmonella typhimurium
that are known antibacterial targets (Chittum and
Champney, 1995; Egebjerg et al., 1989; Kornder,
2002; Lin et al., 1997; Neu and Gootz, 1996;
Schnappinger and Hillen, 1996). Of course, not all
current drug targets are perfect examples; indeed,
many of the drugs that target them are toxic to
humans and resistance has begun to emerge in
many cases. Nevertheless, treatments which utilize
these targets have been shown to be effective in
disease control, and so novel targets possessing
similar characteristics to known targets may be
useful.
The SwissProt species and protein ID codes of
each hit in the BLAST results were compared
to a look-up table (ftp://beta.rcsb.org/pub/pdb/
uniformity/derived data/) to ﬁnd out whether any
homologues of the query gene had an entry in the
PDB database (ftp://ftp.ncbi.nih.gov/genomes/H
sapiens/protein/). A protein with a known struc-
ture is more attractive from the point of view of fur-
ther research, as structure-based drug design can be
carried out straightaway. A protein with sequence
homology to a protein of known structure is likely
to have a similar structure (although this is not
always true) and so may be favoured as a potential
novel drug target.
Each protein was then submitted to several
more restricted BLAST searches against selected
bacterial genomes. The BLAST searches were
restricted by gi number; speciﬁcally the gi numbers
of genes found to be essential or involved in
virulence. These genomes chosen are listed in
Table 3.
These genomes were selected as they cover a
wide range of bacterial types, and also because
they are well characterized and are amongst the few
species for which this work has been carried out to
any great extent. For those species for which this
kind of work has not been done, genomics methods
may allow us to predict essentiality or involve-
ment in virulence. Proteins that have signiﬁcant hits
against essential genes or genes involved in viru-
lence are likely to have the same characteristics
themselves and so may score highly as potential
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Table 3. List of genomes used for restricted BLAST
searches against essential genes or genes involved in
virulence
Essential genes
Genomes Bacillus subtilis (Kobayashi et al., 2003)
Escherichia coli K12
(http://www.shigen.nig.ac.jp/ecoli/pec/
About.html)
Mycobacterium tuberculosis (Sassetti et al.,
2003)
Staphylococcus aureus (Forsyth et al., 2002)
Virulence genes
Genomes Bacillus anthracis (Hoffmaster and Koehler,
1999; Koehler, 2002)
Escherichia coli O157:H7 EDL993 (Brunder
et al., 2001; Sharma and Dean-Nystrom,
2003; Stuber et al., 2003; Wang et al., 2002)
Mycobacterium tuberculosis (Triccas and
Gicquel, 2000)
Neisseria meningitidis (Sun et al., 2000)
Staphylococcus aureus (Dunman et al., 2001)
drug targets. The more ‘model’ genomes in which
the gene is found to be essential, the more likely
it is that this gene is indeed essential for the query
species, and also has greater potential as a target
for a broad-spectrum antibacterial drug.
Having assigned each gene in the query genome
values for a number of characteristics, these values
could then be weighted, summed and ranked to
produce a list of high-priority potential targets.
This ranking approach was used instead of a
machine learning-based approach, as the ‘training
set’ of known antibacterial targets is very small and
not necessarily optimal (see Introduction). While
the ranking approach is more subjective, it does
allow targets to be prioritized which score better
according to our metrics than currently known
targets.
Assigning weights and the robustness of target
prioritization
A number of different weighting schemes were
tried so that the weighting scheme could be reﬁned
to reﬂect the relative importance of the various met-
rics. After a weighting scheme was run on the raw
data, the scores for each metric could be summed
and the total scores of the targets then ranked.
The reﬁnement of the weightings was done by
carrying out a sensitivity analysis on the metric
scores for the top few ranking targets. Sensitivity
analysis is more normally used in biology to ﬁnd
the importance, or so-called control coefﬁcients
(http://dbk.ch.umist.ac.uk/mca home.htm; Fell,
1996; Heinrich and Schuster, 1996; Kell and West-
erhoff, 1986), by which each enzyme controls the
ﬂux through a metabolic pathway, but can in fact be
used to ﬁnd the relative importance of any variable
which contributes to a total. The equation giving
the sensitivity of overall metric A to individual met-
ric vi is given by (equation 1)
C A
i =
∂A
∂vi
·
vi
A
=
∂ lnA
∂ lnvi
(1)
Here a more discretized sensitivity analysis was
done for each target by taking the score of each
metric of the target, ﬁnding 1% of this score, divid-
ing this number by the total score and multiply-
ing by 100. When this is done for all metrics,
these ‘contributions’ sum to 1. Thus, sensitivity
analysis asks, ‘By altering the score of one vari-
able by 1%, what percentage change would this
induce in the total score?’. These sensitivity analy-
ses could clearly show when some variables were
exerting too much or too little inﬂuence on the
total score and therefore the weights could be opti-
mized accordingly. This novel approach proved
very useful in carefully modifying the scoring
systems.
Using different weighting schemes also allowed
the analysis of how robust a particular high-ranking
target was to the weighting scheme. Clearly, a
target which scores highly due to having favourable
characteristics in one highly weighted metric is less
good than one which ranks highly under a number
of different scoring systems.
For each of ﬁve different scoring systems
(Table 4) used on S. aureus, E. coli O157:H7
EDL993 and M. tuberculosis the top 20 ranking
targets were recorded. These top 20 lists could
then be checked against each other to see whether
robust targets had emerged. The top 20 lists were
then cross-checked to see whether any targets were
robust in all three species (see Table 5). This ‘vot-
ing’ method approach can be seen as combining the
output of several weak learners, which is known to
be a very effective approach to data mining (Bauer
and Kohavi, 1999; Dietterich, 2000; Hastie et al.,
2001).
The ﬁrst scoring system was designed to give
most inﬂuence to those metrics which were felt to
be the most important and least inﬂuence to those
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Table 5. The overall top ten ranking targets
Rank Gene name/description Robustness Total score
1 tRNA methyltransferase (trmD) 15 13391
2 UDP-N-Acetylmuramate-L-alanine ligase (murC) 15 13229
3 UDP-N-acetylglucosamine 1-carboxyvinyl transferase (murA)∗ 13 13059
4 Translation initiation factor IF-1 (infA) 14 13019
5 DNA polymerase III, α chain (dnaE) 13 12992
6 30S ribosomal protein S4 (rpsD)∗ 11 12779
7 UDP-N-acetylmuramoylalanine-D-glutamate ligase (murD) 11 12766
8 50S ribosomal protein L10 (rplJ) 11 12755
9 Chromosomal replication initiator protein (dnaA) 10 12716
10 UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-diaminopimelate ligase (murE) 9 12573
These targets rank highly in all three species used and rank in the top 20s of most of the scoring systems used. Robustness is how many times
the gene ranks in the top 20 under ﬁve different scoring systems across the three species used, giving a maximum robustness score of 15.
Total score is the sum of the scores for this target in all scoring systems across all species used. The maximum possible total score is 24120.
∗ Indicates that the gene is a known target of an antibacterial drug (murA is targeted by fosfomycin and rpsD is a target of tetracyclines).
felt to be least important. Homology to essential
genes in M. tuberculosis and S. aureus, and homol-
ogy to virulence genes in Bacillus anthracis were
weighted lower than homology to essential and vir-
ulence genes in other organisms. This was done to
reﬂect the quality of the data for these organisms,
as different methods were used and lists of essential
and virulence genes are not always complete.
Under the second scoring system all metrics were
weighted equally, so that a maximum score for one
metric would be the same as for another. For the
other three scoring systems most of the metrics
were weighted as under the ﬁrst system. However,
in the third scoring system homology to virulence
genes was given greater inﬂuence, in the fourth
homology to essential genes was given greater
weight, and in the ﬁfth the level of conservation of
the target in pathogens was given more importance.
Further investigation of high-scoring targets
Having narrowed down the number of potential
drug targets using the methods outlined above,
the highest-scoring targets could then be investi-
gated in greater detail. The top genes were again
subjected to a BLAST search against the Swis-
sProt database to determine in which pathogens
they were present. The databases Genbank, EMBL
and DDBJ were also searched via ENTREZ
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi)
to ﬁnd whether or not a copy of the query gene
existed in a speciﬁc pathogen, in case this had been
missed by searching only the SwissProt database.
PROSITE (http://us.expasy.org/prosite/) was also
searched to ﬁnd any conserved motifs not identiﬁed
by BLAST, which could be used to ﬁnd more
distantly related homologues of the query gene.
This approach was able to identify any human
sequences which, although not closely related in
terms of sequence homology, could be very sim-
ilar in terms of structure and biochemical proper-
ties to the query gene. Multiple sequence align-
ments and phylogenetic trees were created using
ClustalX (Thompson et al., 1997) and Mega2.1
(Kumar et al., 2001). This was done to deter-
mine how distinct the genes in these pathogens
were from those homologues in non-pathogens and
eukaryotes, and just how well the ‘active sites’
of these genes were conserved across the differ-
ent pathogenic species. The available literature was
also searched to gain more insights into these sug-
gested targets.
Results and discussion
Scores
According to the scoring systems used, the major-
ity of genes in S. aureus, E. coli O157:H7 EDL993
and M. tuberculosis would make very poor antibac-
terial targets (see Figures 2–4). In all three bacteria
there are also only a few high-scoring genes. The
highest ranking of these seem to be fairly robust
and tend to rank in the top 20, regardless of which
scoring system is used (see Table 5).
It is also apparent there are no targets which are
perfect in every way. To obtain a perfect score
in the present metrics a target should be present
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in one copy, be present in all pathogens but not
in non-pathogens, eukaryotes or humans. It should
be perfectly conserved across all pathogens. Its
function should be known, it should be homologous
to a known target, homologous to essential and
virulence genes in all the model genomes used
and its structure should be known. Here even the
highest-ranking targets achieve only some 50% of
the perfect score.
This is perhaps discouraging, as it means that
there is little possibility for the development of
a ‘magic bullet’ drug that is highly effective,
speciﬁcally targets only pathogens, is easy to
develop and is immune to the problems of emerg-
ing resistance. However, this never was a likely
prospect.
The unusual peaks in the distribution graphs
are due to genes of unknown function that, when
submitted to BLAST with an expectation value of
0.01, did not return any hits. The two peaks in
E. coli O157:H7 EDL993 target scores occur for
the same reason, except that the peak at the higher
score is due to genes that return no hits but have
been assigned some sort of function, presumably
by other methods.
Scoring systems and sensitivity analysis
The ﬁrst scoring system used was designed to
reﬂect what is thought to be most important in
terms of the properties an antibacterial drug tar-
get should possess. Hence, the ﬁrst scoring sys-
tem rates as very important the properties ‘species
distribution’, ‘conservation in pathogens’, ‘similar-
ity to human’ and ‘homology to essential genes’.
A target which does not perform well on any one
of these criteria will probably not make a good
drug target. The emphasis accorded to these prop-
erties means that targets which are not present in
a wide range of pathogens, are not well conserved,
are very similar to targets in humans, or are not
essential will not be able to score highly and thus
will not be prioritized. The metric ‘species distri-
bution’ is weighted so that a target will receive the
maximum score if it is present in all the bacteria
treated as pathogenic by this study and in no non-
pathogens. It is unlikely that this maximum would
ever be awarded to a target, and so this property
is given a very high weighting to compensate for
this fact. The other useful properties a target may
possess are, in a sense, bonuses and are scored to
reﬂect this. A target does not necessarily need to
be (directly) involved in virulence in order for a
drug to neutralize an infection. However, involve-
ment in virulence may bring beneﬁts to using a
target, in that the target should be absent from most
non-pathogens and also absent from humans. The
existence of homologues in humans does not mat-
ter per se; rather, it is the similarity (or lack) of
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Figure 2. Frequency distribution of scores for potential targets in Staphylococcus aureus, based on the ﬁrst scoring
system used
Copyright  2004 John Wiley & Sons, Ltd. Comp Funct Genom 2004; 5: 304–327.Assessment of novel antibacterial targets 313
1200
1000
800
600
400
200
0
0
 
a
n
d
 
1
9
2
0
 
a
n
d
 
3
9
4
0
 
a
n
d
 
5
9
6
0
 
a
n
d
 
7
9
8
0
 
a
n
d
 
9
9
1
0
0
 
a
n
d
 
1
1
9
1
2
0
 
a
n
d
 
1
3
9
1
4
0
 
a
n
d
 
1
5
9
1
6
0
 
a
n
d
 
1
7
9
1
8
0
 
a
n
d
 
1
9
9
2
0
0
 
a
n
d
 
2
1
9
2
2
0
 
a
n
d
 
2
3
9
2
4
0
 
a
n
d
 
2
5
9
2
6
0
 
a
n
d
 
2
7
9
2
8
0
 
a
n
d
 
2
9
9
3
0
0
 
a
n
d
 
3
1
9
3
2
0
 
a
n
d
 
3
3
9
3
4
0
 
a
n
d
 
3
5
9
3
6
0
 
a
n
d
 
3
7
9
3
8
0
 
a
n
d
 
3
9
9
4
0
0
 
a
n
d
 
4
1
9
4
2
0
 
a
n
d
 
4
3
9
4
4
0
 
a
n
d
 
4
5
9
4
6
0
 
a
n
d
 
4
7
9
4
8
0
 
a
n
d
 
4
9
9
5
0
0
 
a
n
d
 
5
1
9
5
2
0
 
a
n
d
 
5
3
9
5
4
0
 
a
n
d
 
5
5
9
5
6
0
 
a
n
d
 
5
7
9
5
8
0
 
a
n
d
 
5
9
9
6
0
0
 
a
n
d
 
6
1
9
6
2
0
 
a
n
d
 
6
3
9
6
4
0
 
a
n
d
 
6
5
9
6
6
0
 
a
n
d
 
6
7
9
6
8
0
 
a
n
d
 
6
9
9
7
0
0
 
a
n
d
 
7
1
9
F
r
e
q
u
e
n
c
y
Score between
Figure 3. Frequency distribution of scores for potential targets in Escherichia coli O157:H7 EDL993, based on the ﬁrst
scoring system used
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Figure 4. Frequency distribution of scores for potential targets in Mycobacterium tuberculosis, based on the ﬁrst scoring
system used
the target to a human homologue which is impor-
tant. Again, this is reﬂected in the scoring system,
with the number of human homologues being less
important than proximity. Of course the lack of
any human homologues will bring other beneﬁts,
such as the reduced need for QSAR studies to ﬁnd
lead compounds that will selectively target only
the bacterial version of a protein. In a similar way
‘known function’ and ‘entry in PDB’ are not crucial
properties that a potential target must possess. They
simply imply that something is already known
about these targets which can be used as a jumping-
off point for further investigation. ‘Copy number’
could be potentially important as, if a protein exists
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in several copies and a drug targets only one copy,
it is possible that a non-targeted copy could take
over the function of the target, thus rendering the
drug useless. However, it is likely that drugs which
can disrupt the function of one copy will disrupt the
function of both. Therefore, copy number is given
a low/intermediate weighting in the scoring sys-
tem. (Multiple paralogues also make the develop-
ment of resistance much less likely.) The properties
‘eukaryotic homologues’ and ‘mouse homologues’
are not crucial, but again may make the process of
drug development easier. A target without homo-
logues in animal models will be more useful when
it comes to carrying out animal trials. The lack of
eukaryotic homologues may also allow the use of
the target in developing drugs for livestock. The
property ‘homology to known target’ is weighted
fairly low in the ﬁrst scoring system. Homology
to a known target may imply something about the
biochemical properties of a target which may be
relevant to the drug design process. However, tar-
gets currently in use are not necessarily the best
available, as problems with toxicity and resistance
indicate. This study is also aimed at ﬁnding novel
targets, which is why this property was not treated
as being very important. The other scoring sys-
tems used are variants of this ﬁrst scoring system,
with the exception of the second, which simply
treats all metrics as being equally important. The
function of these scoring systems is to perturb the
top-ranking targets, to weed out those targets which
only perform well because of the vagaries of one
scoring system.
We used sensitivity analyses on the top ﬁve
ranking targets of S. aureus under the ﬁve dif-
ferent scoring systems (Figures 5–9) and also
show the sensitivity analyses of lowest-ranking
(Figure 10) and middle-ranking (Figure 11) targets
from S. aureus under the ﬁrst scoring system used.
It can be seen that in most cases homology to viru-
lence genes does not make much of a contribution
to the total score of the top-ranking targets. This
is generally because, unlike essential genes, viru-
lence genes occur in only a limited spectrum of
pathogens. As virulence genes tend to be more or
less speciﬁc to one mode of pathogenicity, they
do not occur in such a broad spectrum of organ-
isms and consequently perform poorly in the metric
‘distribution in bacteria’ and ‘distribution of homo-
logues’. Similarly, when proteins do show homol-
ogy to virulence genes in one pathogen, they often
have no hits against virulence genes from other
pathogens (e.g. see Figure 5).
The top-ranking targets in any scoring system
also seem to have very similar sensitivity pro-
ﬁles, each generally being homologous to essen-
tial genes in all of the species used, having no
homologues in humans and being well-conserved
in a wide range of pathogens. Where target pro-
ﬁles differ is in the extent of the gene’s dis-
tribution amongst pathogens, the extent of con-
servation (although not much), whether or not a
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Figure 5. The contribution of each metric to the total score of the top ﬁve ranking targets in Staphylococcus aureus,b a s e d
on the ﬁrst scoring system used. Numbers refer to metrics described in Table 6. trmD is the top ranking (1st) target under
this scoring system
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structure is known, whether or not the gene is
homologous to a known target, and whether or not
the target is homologous to any virulence genes.
From Figure 6 it seems that the in the proﬁles
of the lowest-ranking targets the metric ‘similar-
ity to human homologue’ becomes relatively more
important. This is simply because these targets
score so poorly on most of the other metrics.
Many of these lower-ranking targets are hypo-
thetical or unknown proteins which do not return
many (if any) hits when submitted to BLAST,
so are poorly characterized and score accordingly.
Figure 7 shows that the proﬁles of middle-ranking
targets vary. These targets score well on several
criteria but poorly in others, such as the number
of human homologues or homology to essential
genes.
High-ranking targets
A number of genes rank not only consistently
highly under the ﬁve scoring systems used, but
also appear in the top 20 targets in all three of the
genomes used in this study (see Table 5). Of these,
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Figure 6. The contribution of each metric to the total score of the top ﬁve ranking targets in Staphylococcus aureus,b a s e d
on the second scoring system used. Numbers refer to metrics described in Table 6
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Figure 7. The contribution of each metric to the total score of the top ﬁve ranking targets in Staphylococcus aureus,b a s e d
on the third scoring system used. Numbers refer to metrics described in Table 6. trmD ranks ﬁfth from top under this
scoring system
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Figure 8. The contribution of each metric to the total score of the top ﬁve ranking targets in Staphylococcus aureus,b a s e d
on the fourth scoring system used. Numbers refer to metrics described in Table 6. trmD is the top ranking target under
this scoring system, while IF-1 (infA) ranks ﬁfth
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Figure 9. The contribution of each metric to the total score of the top ﬁve ranking targets in Staphylococcus aureus,b a s e d
on the ﬁfth scoring system used. Numbers refer to metrics described in Table 6. IF-1 is the top ranking target under this
scoring system, while trmD ranks second
UDP-N-acetylglucosamine 1-carboxyvinyltransfer-
ase (murA) is a known target of fosfomycin, and
the 30S ribosomal subunit protein S4 (rpsD) is
a known target of tetracyclines. Of the others,
dnaE, murC, murD and murE have been previ-
ously suggested as potential drug targets (Bouhss
et al., 1997; El Zoeiby et al., 2003; Inoue et al.,
2001; Marmor et al., 2001; Projan, 2002; Tanner
et al., 1996), and work carried out on murC, murD
and murE has revealed effective inhibitors of these
proteins (El Zoeiby et al., 2003; Marmor et al.,
2001; Tanner et al., 1996). The ribosome is of
course currently heavily targeted by antibacterial
drugs and suggestions for further work on riboso-
mal proteins have been made previously (Knowles
and King, 1998). The existence of several known
and previously suggested targets in the overall top
10 ranking in a sense validates this study, as it
indicates that this method of target prioritization is
indeed able to identify useful targets. There follows
a brief discussion of the potential of some of the
novel targets suggested.
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Figure 10. The contribution of each metric to the total score of the ﬁve lowest ranking targets in Staphylococcus aureus
based on the ﬁrst scoring system used. Numbers refer to metrics described in Table 6
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Figure 11. The contribution of each metric to the total score of ﬁve mid-ranking targets in Staphylococcus aureus based on
the ﬁrst scoring system used. Numbers refer to metrics described in Table 6
tRNA methyltransferase (trmD)
tRNA methyltransferase (trmD) catalyses the trans-
fer of a methyl group from S-adenosyl-L-methio-
nine (AdoMet) to G37 within a subset of bacterial
tRNA species, which have a G residue at the 36th
position (Ahn et al., 2003). It is essential for the
maintenance of the correct reading frame during
translation. As an enzyme it is probably a bet-
ter target than those requiring the inhibition of
protein–protein interactions, although we note that
progress in ﬁnding inhibitors of these is now being
made (Oneyama et al., 2002; Paulmurugan et al.,
2004).
The structure of the enzyme has been deter-
mined and is available from the Protein Data
Bank (http://www.rcsb.org/pdb/) (Accession Nos
1UAJ, 1UAK, 1UAL and 1UAM) (Ahn et al.,
2003). The active site regions of the enzyme, which
binds to AdoMet and tRNA, are known and are
illustrated in Figure 12. It can be seen that these
active site regions are highly conserved. This is
encouraging from the point of view of designing
a broad-spectrum drug to target this enzyme and
also in terms of the reduced potential for resistant
mutants emerging.
TrmD has, to our knowledge, never been rec-
ommended as an antibacterial drug target in
the scientiﬁc literature, although it — along with
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Table 6. Key to the metrics used
Number Description of metric
1 Copy number
2 Distribution of homologues (i.e. how many
homologues in non-pathogens vs. pathogens?)
3 Distribution in pathogens (i.e. how many distinct
pathogens is the gene present in, and in how many
discrete non-pathogens?)
4 Conservation in pathogens
5 Number of homologues in eukaryotes
6 Number of human homologues
7 Similarity to human homologue
8 Number of mouse homologues
9 Lactobacillus plantarum homologues
10 Function known?
11 Homology to known target
12 Homology to essential gene in Bacillus subtilis
13 Homology to essential gene in Escherichia coli K12
14 Homology to essential gene in Mycobacterium
tuberculosis
15 Homology to essential gene in Staphylococcus aureus
16 Homology to virulence gene in Bacillus anthracis
17 Homology to virulence gene in Escherichia coli
O157:H7 EDL993
18 Homology to virulence gene in Mycobacterium
tuberculosis
19 Homology to virulence gene in Neisseria meningitidis
20 Homology to virulence gene in Staphylococcus aureus
21 Homology to PDB entry
a large batch of other bacterial proteins — has
been patented on the basis of experiments in
S. aureus in connection with its use as a drug tar-
get (United States Patent and Trademark Ofﬁce
http://www.uspto.gov/, Patent No. 6187541).
Figure 13 shows a neighbour-joining tree of
trmD sequences in pathogenic and non-pathogenic
bacteria. As can be seen, trmD is present in many
pathogens, both Gram-positive and Gram-negative,
indicating that it has the potential to be a very
good broad-spectrum antibacterial drug target. The
enzyme appears to function as a dimer (Ahn et al.,
2003), so one would probably seek to target the
active site.
It is also important to know in which pathogens
trmD is absent. Table 7 shows which of the
pathogens (as deﬁned by this study) are not known
to possess trmD. It is important to note, how-
ever, that only a small number of these strains
Table 7. List of pathogenic bacteria (as deﬁned by this
study) which are not known to possess any homologues of
the trmD gene under the expectation value used
Bacillus cereus
Bordetella pertussis
Brucella abortus
Clostridium botulinum
Clostridium tetani∗
Corynebacterium diptheriae
Enterococcus faecium
Escherichia coli 0111:H−
Escherichia coli O127:H6
Flavobacterium
meningosepticum
Francisella tularensis
Haemophilus parainﬂuenzae
Klebsiella pneumoniae
Legionella pneumophila
Moraxella catarrhalis
Moraxella lacunata
Mycoplasma fermentans
Mycoplasma hominis
Neisseria gonorrhoeae
Neisseria meningitidis serogroup C
Propionibacterium acnes
Proteus mirabilis
Providencia rettgeri
Providencia stuartii
Salmonella cholerae-suis
Salmonella enteritidis
Shigella dysenteriae
Staphylococcus capitis
Staphylococcus epidermidis∗
Staphylococcus saprophyticus
Streptococcus agalactiae
Streptococcus agalactiae serotype III∗
Streptococcus pyogenes serotype M5∗
Vibrio parahaemolyticus∗
Wolinella recta
Wolinella succinogenes
Xanthomonas maltophila
∗ Species/strains whose genomes have been entirely sequenced.
Figure 12. (A) Alignment of trmD sequences found in pathogens. trmD sequences from S. aureus, E. coli O157:H7 EDL993
and M. tuberculosis were used as BLAST queries and the (non-redundant) hits from these searches were combined.
BLAST was run with an expectation value of 0.01. A sequence from Acinetobacter calcoaceticus was removed, as it was
considerably shorter than the others. Active site regions are highlighted by black boxes and labels show the function of
t h ea c t i v es i t ea f t e rA h net al. (2003). Sequences were aligned using ClustalX (Thompson et al., 1997). Names are given
as SwissProt style ID codes: TRMD MYCPN is for trmD from Mycoplasma pneumoniae;M Y C G E ,Mycoplasma genitalium;
UREUR, Ureaplasma urealyticum;B O R B U ,Borrelia burgdorferi; TREPA, Treponema pallidum;L I S M O ,Listeria monocytogenes;
BACAN, Bacillus anthracis;E N T F A ,Enterococcus faecalis; STRPY, Streptococcus pyogenes; STRPN, Streptococcus pneumoniae;
STRA5, Streptococcus agalactiae serotype V; STRMU, Streptococcus mutans; STAAN, Staphylococcus aureus N315; CLOPE,
Clostridium perfringens; MYCTU, Mycobacterium tuberculosis;M Y C L E ,Mycobacterium leprae; TROWH, Tropheryma whipplei;
CHLTR, Chlamydia trachomatis;C H L M U ,Chlamydia muridarum;C H L P N ,Chlamydia pneumoniae; ECO57, Escherichia coli
O157:H7 EDL993; SHIFL, Shigella ﬂexneri; SALTY, Salmonella typhimurium;Y E R P E ,Yersinia pestis;V I B V U ,Vibrio vulniﬁcus;
VIBCH, Vibrio cholerae;P A S M U ,Pasteurella multocida;H A E I N ,Haemophilus inﬂuenzae;H A E D U ,Haemophilus ducreyi;P S A E A ,
Pseudomonas aeruginosa;N E I M A ,Neisseria meningitidis;R I C P R ,f o rRickettsia prowazekii; RICCN, Rickettsia conorii;B R U M E ,
Brucella melitensis;C A M J E ,Campylobacter jejuni;H E L P Y ,Helicobacter pylori. (B) Alignment of selected trmD sequences from
pathogenic bacteria and a human homologue (marked *). It can be seen that the human homologue only aligns with the
bacterial proteins at the C-terminal end. See Figure 12 for further information
Copyright  2004 John Wiley & Sons, Ltd. Comp Funct Genom 2004; 5: 304–327.Assessment of novel antibacterial targets 319
Recognition of tRNA general structure AdoMet binding pocket
AdoMet binding pocket Lid
A
Recognition of tRNA general structure
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Figure 12. Continued
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TRMD Streptococcus pyogenes (serotype M3)
TRMD Streptococcus pyogenes
TRMD Streptococcus pyogenes (serotype M18)
TRMD Streptococcus pneumoniae
TRMD Streptococcus agalactiae (serotype V)
TRMD Streptococcus mutans
TRMD Lactococcus lactis (subsp. lactis)
TRMD Bacillus subtilis
TRMD Bacillus anthracis
TRMD Bacillus halodurans
TRMD Enterococcus faecalis
TRMD Listeria monocytogenes
TRMD Listeria innocua
TRMD Staphylococcus aureus (strain N315)
TRMD Staphylococcus aureus (strain Mu50)
TRMD Staphylococcus aureus (strain MW2)
TRMD Thermoanaerobacter teng congensis
TRMD Clostridium perfringens
TRMD Clostridium acetobutylicum
TRMD Borrelia burgdorferi
TRMD Treponema pallidum
TRMD Aquifex aeolicus
TRMD Fusobacterium nucleatum (subsp. nucleatum)
TRMD Thermotoga maritima
TRMD Ureaplasma parvum
TRMD Ureaplasma urealyticum
TRMD Mycoplasma pulmonis
TRMD Mycoplasma gallisepticum
TRMD Mycoplasma pneumoniae
TRMD Mycoplasma genitalium
TRMD Chlamydia trachomatis
TRMD Chlamydia muridarum
TRMD Chlamydia pneumoniae
TRMD Buchnera aphidicola (subsp. Schizaphis graminum)
TRMD Buchnera aphidicola (subsp. Acyrthosiphon pisum)
TRMD Buchnera aphidicola (subsp. Baizongia pistaciae)
TRMD Neisseria meningitidis (serogroup B)
TRMD Neisseria meningitidis (serogroup A)
TRMD Xylella fastidiosa
TRMD Xylella fastidiosa (strain Temecula1)
TRMD Xanthomonas campestris (pv. campestris)
TRMD Xanthomonas axonopodis (pv. citri)
TRMD Ralstonia solanacearum
TRMD Pseudomonas aeruginosa
TRMD Pasteurella multocida
TRMD Haemophilus influenzae
TRMD Haemophilus ducreyi
TRMD Vibrio vulnificus
TRMD Vibrio cholerae
TRMD Serratia marcescens
TRMD Yersinia pestis
TRMD Salmonella typhi
TRMD Salmonella typhimurium
TRMD Shigella flexneri
TRMD Escherichia coli O157:H7
TRMD Escherichia coli
TRMD Escherichia coli O6
TRMD Mycobacterium tuberculosis
TRMD Mycobacterium leprae
TRMD Corynebacterium glutamicum
TRMD Streptomyces coelicolor
TRMD Tropheryma whipplei
TRMD Deinococcus radiodurans
TRMD Rickettsia prowazekii
TRMD Rickettsia conorii
TRMD Caulobacter crescentus
TRMD Brucella melitensis
TRMD Rhizobium loti
TRMD Agrobacterium tumefaciens (strain C58)
TRMD Rhizobium meliloti
TRMD Chlorobium tepidum
TRMD Anabaena sp. (strain PCC 7120)
TRMD Synechocystis sp. (strain PCC 6803)
TRMD Campylobacter jejuni
TRMD Helicobacter pylori
TRMD Helicobacter pylori J99
DCA3 Brassica juncea
DCA1 Arabidopsis thaliana 99
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Figure 13. Neighbour-joining tree showing the distribution of trmD in pathogenic and non-pathogenic bacteria. Sequences
were aligned in ClustalX (Thompson et al., 1997) (trmD from Acinetobacter calcoaceticus was removed, as it is considerably
shorter than the other trmD sequences). The tree was created using Mega 2.1 using default parameters (Kumar et al.,
2001). Branches leading to Gram-negative bacteria are coloured blue, those leading to Gram-positive bacteria in red,
and those leading to Cyanobacteria in dark green. The tree is rooted using DCA3 from Brassica juncea and DCA1 from
Arabidopsis thaliana as the outgroup (branches highlighted in purple). trmD sequences from bacteria treated as pathogenic
by this study are marked with a red diamond. Numbers on branches show bootstrap support for groupings based on 100
replicates (values <50 are not shown). Scale bar shows number of substitutions per site
have been extensively sequenced (those marked
*). Thus, a copy of the gene may exist in
these species/strains despite its absence from the
databases. As can be seen, there are only a small
number of species/strains which have been entirely
sequenced and which do not possess a copy of
trmD.
While there is a version of trmD in humans,
the human version of the protein covers only
covers the C-terminal end of the bacterial protein,
as illustrated by Figure 12B. This may allow a
selective drug to be developed which targets the
bacterial but not the human version of the protein.
Another issue of importance in the development
of a new drug is ease of assay development (All-
sop, 1998). If a copy of a protein exists in yeast,
then in vitro assay development is fairly straight-
forward via haploinsufﬁcient phenotype (hp)-based
strategies (Giaever et al., 1999). However, no trmD
homologue exists in yeast, so an alternative strategy
must be used here. Other assays will of course be
necessary for cellular functional assays and analy-
sis in vivo.
Translation initiation factor IF-1 (infA)
Translation initiation factor IF-1 scores well on all
criteria except for homology to virulence genes,
homology to known targets and the number of
homologues in eukaryotes. IF-1 is very well con-
served in pathogens, and this contributes signiﬁ-
cantly to its high score.
The precise function of initiation factor IF-1 is
unknown. However, it is known to be one of a num-
ber of factors essential for the establishment of the
correct reading frame during translation (Dahlquist
and Puglisi, 2000). It is therefore one determinant
of translation accuracy. IF-1 is essential for cell
viability and cells deﬁcient in IF-1 exhibit few
polysomes (Cummings and Hershey, 1994).
IF-1 is also well conserved across all the
species/strains in which it is present, and thus a
drug could be designed to attack this target in a
broad spectrum of pathogens. A number of residues
are identical in all sequences, perhaps indicat-
ing a high selection pressure against mutation at
these positions. This is encouraging from the point
of view of drug resistance. Any resistant strains
arising through mutation of these residues could
be severely attenuated compared to the wild-type
form.
It has been observed that IF-1 contains a repeated
sequence motif (S1-RM) which is also found in
ribosomal protein S1 (whose function is to enhance
translational initiation in Gram-negative bacteria)
(Gribskov, 1992). Thus, a drug designed to tar-
get this motif could attack two different essential
gene products at the same time, which would be
highly advantageous from the point of view of
drug resistance. This motif appears to be involved
in RNA binding. However, this motif is also
found in eukaryotic translation initiation factor α-
chains (http://us.expasy.org/prosite/) and several
copies of this exist in humans. Figure 14 shows
the sequences of IF-1 in pathogens aligned against
the three eIF-1α sequences found in humans.
A number of positions in the alignment are
highly conserved in both humans and pathogens,
so some skill may be required to develop a
drug which targets pathogens but is not toxic
to humans. This highlights the problem of using
overall sequence similarity to determine the close
functional and biochemical relatives of a gene
product.
Nevertheless, there do exist cases of success-
ful drugs which target proteins which are also
present in humans, such as the antifungal strobil-
urins which target cytochrome bc1 (Weber et al.,
1990). It can also be seen from Figure 14 that
there are a number of positions in the protein
where all or most pathogenic sequences have one
residue (or biochemically similar residues) but
where human sequences possess a biochemically
different residue. Therefore, there is still plenty of
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Figure 14. Alignment of IF1 proteins in pathogens and human eIF-1α sequences (bottom three sequences, marked *).
Some identical sequences from close relatives of species/strains shown are omitted for ease of presentation. The alignment
was created using ClustalX (Thompson et al., 1997). As can be seen, a number of positions are highly conserved in both
human and pathogen sequences. Black arrows mark positions where the majority of pathogens share the same or similar
residues but where human sequences possess a different residue. IF1 CHLTR is for IF-1 from Chlamydia trachomatis;
CHLPN, Chlamydia pneumoniae;M Y C P E ,Mycoplasma penetrans;U R E U R ,Ureaplasma urealyticum;M Y C P N ,Mycoplasma
pneumoniae;M Y C G E ,Mycoplasma genitalium;C A M J E ,Campylobacter jejuni;H E L P Y ,Helicobacter pylori;N E I M A ,Neisseria
meningitidis serogroup A; RICPR, Rickettsia prowazekii; RICCN, Rickettsia conorii;B R U M E ,Brucella melitensis;E C O 5 7f o r
Escherichia coli O157:H7 EDL993; YERPE, Yersinia pestis;V I B C H ,Vibrio cholerae;H A E I N ,Haemophilus inﬂuenzae;P A S M U ,
Pasteurella multocida;P S E A E ,Pseudomonas aeruginosa; STAAN, Staphylococcus aureus N315; BACAN, Bacillus anthracis;
LISMO, Listeria monocytogenes;E N T F A ,Enterococcus faecalis; STRPY, Streptococcus pyogenes; STRA5, Streptococcus agalactiae
serotype V; CLOPE, Clostridium perfringens; MYCTU, Mycobacterium tuberculosis; TROWH, Tropheryma whipplei;L E P I N ,
Leptospira interrogans; TREPA, Treponema pallidum;B O R B U ,Borrelia burgdorferi;H U M A N ,Homo sapiens
potential for the development of a drug which tar-
gets pathogens without interfering with the human
form of the protein.
The structure of IF-1 has been determined
and is available from the Protein Data Bank
(http://www.rcsb.org/pdb/) (Accession Nos
1HRO and 1AH9). IF-1 is known to function as
a monomer.
Figure 15 shows a phylogenetic tree of IF-
1 and its homologues. It can be seen that the
eukaryotic (chloroplast) sequences and those from
bacteria can be split fairly well. Sequences from
humans and pathogenic bacteria can be split easily.
The sequences from pathogens and non-pathogens
cannot be split, at least at the whole-sequence level,
so it may prove impossible to develop a drug
which targets IF-1 only in pathogens. This is not
necessarily something to be overly concerned with,
however, as curing the disease is more important
than preserving the commensal ﬂora.
There are a number of pathogens in which IF-
1 has not been found (see Table 8). Again, this
does not necessarily mean these pathogens do not
possess a copy, as in many cases whole-genome
sequencing has not been carried out. As can be
seen, there are only a small number of species
which have been entirely sequenced and in which
IF-1 is absent.
Conclusions
This study has used a simple but rational collec-
tion of criteria on which to rate bacterial gene
products as potential broad-spectrum antibacterial
drug targets. We assessed all the proteins from
S. aureus, E. coli O157:H7 EDL993 and M. tuber-
culosis on criteria such as distribution, essentiality
and involvement in virulence. All the proteins from
each of these organisms were ranked in order of
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suitability as a potential drug target. It has been
shown that although only a small proportion of
gene products in any of the genomes would make
useful drug targets, those which do rank highly do
so fairly independently of the scoring system used.
From these rankings it has been found that not only
do a number of proteins rank highly under most
or all of the different scoring systems used, but
they also rank highly in all three genomes used.
These targets have been described in some fur-
ther detail and are left as suggestions for further
in-depth analysis.
Table 8. List of pathogenic bacteria (as deﬁned by this
study) which do not possess any homologues of the infA
gene under the expectation value used
Acinetobacter calcoaceticus
Bacillus cereus
Bordetella pertussis
Brucella abortus
Clostridium botulinum
Clostridium tetani∗
Corynebacterium diptheriae
Enterococcus faecium
Escherichia coli O111:H−
Escherichia coli O127:H6
Flavobacterium
meningosepticum
Francisella tularensis
Haemophilus parainﬂuenzae
Klebsiella pneumoniae
Legionella pneumophila
Moraxella catarrhalis
Moraxella lacunata
Mycoplasma fermentans
Mycoplasma hominis
Neisseria gonorrhoeae
Neisseria meningitidis serogroup B∗
Neisseria meningitidis serogroup C
Propionibacterium acnes
Proteus mirabilis
Providencia rettgeri
Providencia stuartii
Salmonella cholerae-suis
Salmonella enteritidis
Shigella dysenteriae
Staphylococcus capitis
Staphylococcus saprophyticus
Streptococcus agalactiae
Streptococcus agalactiae serotype III∗
Streptococcus pyogenes serotype M18∗
Streptococcus pyogenes serotype M5
Vibrio parahaemolyticus∗
Vibrio vulniﬁcus∗
Wolinella recta
Wolinella succinogenes
Xanthomonas maltophila
∗ Species/strains whose genomes have been entirely sequenced.
Figure 15. Neighbour-joiningtree showing the distribution
of infA in pathogenic and non-pathogenic bacteria and
eukaryotes. Sequences were aligned in ClustalX (Thompson
et al., 1997). The tree was created using Mega 2.1
using default parameters (Kumar et al., 2001). Branches
leading to Gram-negative bacteria are coloured blue, those
leading to Gram-positive bacteria in red, those leading
to Cyanobacteria in dark green, and those leading to
eukaryotes in light green. The tree is rooted using RT12
from Petunia hybrida, Brassica napus and Raphanus sativus
as the outgroup (branches highlighted in purple). infA
sequences from bacteria treated as pathogenic by this study
are marked with a red diamond. Human sequences are
marked with a green diamond. Numbers on branches show
bootstrap support for groupings based on 100 replicates
(values <50 are not shown). Scale bar shows number of
substitutions per site
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IF1C Amborella trichopoda
IF1C Cabomba caroliniana
IF1C Cornus mas
IF1C Epifagus virginiana
IF1C Leucophyllum frutescens
IF1C Hedera helix
IF1C Garrya elliptica
IF1C  Brexia madagascariensis
IF1C Zea mays
IF1C Oryza sativa
IF1C Triticum aestivum
IF1C Nicotiana tabacum
IF1C Arabidopsis thaliana
IF1C Pinus thunbergii
IF1Y Homo sapiens
IF1X Homo sapiens
IF1H Homo sapiens
IF1C Nephroselmis olivacea
IF1C Psilotum nudum
IF1C Marchantia polymorpha
IF1C Chaetosphaeridium globosum
IF1C Spirogyra maxima
IF1C Mesostigma viride
IF1 Synechocystis sp. (strain PCC 6803)
IF1 Synechococcus elongatus
IF1 Anabaena sp. (strain PCC 7120)
IF1C Chlorella vulgaris
IF1 Aquifex aeolicus
IF1 Thermoanaerobacter tengcongensis
IF1 Thermotoga maritima
IF1 Bifidobacterium longum
IF1 Streptomyces coelicolor
IF1 Tropheryma whipplei
IF1 Corynebacterium efficiens
IF1 Corynebacterium glutamicum
IF1 Mycobacterium tuberculosis
IF1 Mycobacterium leprae
IF1 Chlorobium tepidum
IF1 Fusobacterium nucleatum (subsp. nucleatum)
IF1 Ureaplasma parvum
IF1 Ureaplasma urealyticum
IF1 Mycoplasma penetrans
IF1 Mycoplasma gallisepticum
IF1 Mycoplasma pneumoniae
IF1 Mycoplasma genitalium
IF1 Helicobacter pylori
IF1 Helicobacter pylori J99
IF1 Campylobacter jejuni
IF1 1Ralstonia solanacearum
IF1 Neisseria meningitidis (serogroup A)
IF1 Leptospira interrogans
IF1 Clostridium perfringens
IF1 Clostridium acetobutylicum
IF1 Bacillus halodurans
IF1 Staphylococcus aureus (strain N315)
IF1 Staphylococcus aureus (strain Mu50)
IF1 Staphylococcus aureus (strain MW2)
IF1 Staphylococcus epidermidis
IF1 Bacillus anthracis
IF1 Oceanobacillus iheyensis
IF1 Bacillus subtilis
IF1 Listeria monocytogenes
IF1 Enterococcus faecalis
IF1 Lactococcus lactis (subsp. lactis)
IF1 Streptococcus mutans
IF1 Streptococcus pneumoniae
IF1 Streptococcus pyogenes (serotype M3)
IF1 Streptococcus pyogenes
IF1 Streptococcus agalactiae (serotype V)
IF1 Escherichia coli O157:H7
IF1 Escherichia coli
IF1 Salmonella typhi
IF1 Shigella flexneri
IF1 Escherichia coli O6
IF1 Salmonella typhimurium
IF1 Yersinia pestis
IF1 Vibrio cholerae
IF1 Haemophilus ducreyi
IF1 Haemophilus influenzae
IF1 Pasteurella multocida
IF1 Shewanella oneidensis
IF1 Wigglesworthia glossinidia brevipalpis
IF1 Buchnera aphidicola (subsp. Schizaphis graminum)
IF1 Pseudomonas aeruginosa
IF1 Chlamydia trachomatis
IF1 Chlamydia muridarum
IF1 Chlamydia pneumoniae
IF12 Ralstonia solanacearum
IF1 Xanthomonas axonopodis (pv. citri)
IF1 Xanthomonas campestris(pv. campestris)
IF1 Xylella fastidiosa
IF1 Xylella fastidiosa (strain Temecula1)
IF1 Rickettsia prowazekii
IF1 Rickettsia conorii
IF1 Caulobacter crescentus
IF1 Rhizobium loti
IF1 Brucella suis
IF1 Brucella melitensis
IF1 Rhizobium meliloti
IF1 Agrobacterium tumefaciens (strain C58)
IF1 Borrelia burgdorferi
IF1 Treponema pallidum
IF1 Deinococcus radiodurans
IF1 Mycoplasma pulmonis
IF1 Mycoplasma sp.
RT12 Petunia hybrida
RT12 Brassica napus
RT12 Raphanus sativus
0.2
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A number of known and previously suggested
targets ﬁgure prominently in the overall top ten
ranking. This shows that the methods used by this
study can successfully identify targets which have
the potential to be useful in the effective treatment
of disease.
Through this study, a number of proteins have
been suggested as entirely novel drug targets. How-
ever, the proof of these post-genomics methods
will be in the successful development of a novel
drug. Indeed, our scoring metrics made no attempt
to consider a number of ‘post-target-identiﬁcation’
criteria such as ‘ease of assay’. Indeed, ‘To date no
antibacterial compounds identiﬁed by target-based
screening have advanced into clinical testing, much
less been used clinically to treat bacterial infec-
tions’ (Projan, 2002). However, we argue that the
two candidates identiﬁed (trmD and infA), as well
as the methods exploited herein, provide promising
strategies for the identiﬁcation of novel antimi-
crobial targets, which can be analysed iteratively
via hypothesis driven methods (Kell and Oliver,
2004). Whilst, of course, having a good target is
hardly the same as having a good drug that inhibits
it, developments of the sensitivity-based scoring
approach could also be used in virtual screening,
in the scoring of targets for ‘druggability’ (Hopkins
and Groom, 2002; Zambrowicz and Sands, 2003)
and of compounds for ‘drug-like’ qualities beyond
the ‘rule of 5’ (Lipinski et al., 2001). In this sense,
multi-objective optimization methods (e.g. those of
Coello Coello et al., 2002; Dasgupta et al., 1999;
Deb, 2001; Knowles et al., 2001; Zitzler, 1999)
might also be used to advantage.
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